STOCK TITAN

VisionWave sets up $30M at-the-market stock plan

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

VisionWave Holdings, Inc. (VWAV) entered into an At The Market Issuance Sales Agreement with Aegis Capital Corp., allowing VisionWave to sell, from time to time, shares of its common stock with an aggregate offering price of up to $30,000,000 under its effective Form S-3 shelf registration.

Sales may be made as at-the-market offerings on the Nasdaq Global Market or in other permitted transactions, with Aegis acting as agent on a commercially reasonable efforts basis. VisionWave will pay a 2.0% commission on gross proceeds and currently intends to use any net proceeds for general corporate and working capital purposes.

Positive

  • None.

Negative

  • None.

Filing Explained

The $30 million ATM is only a ceiling; no shares or proceeds are committed, while any issuance would dilute existing holders.

The filing establishes a potential equity-financing capacity rather than a completed sale: under the effective Form S-3, VisionWave may sell up to $30 million of new common stock, which would increase the share count and reduce existing holders’ percentage ownership if issued.

The $30 million figure is a ceiling, not committed proceeds: the company is not required to sell shares, the agent is not required to buy them as principal, and actual sales depend on company instructions, price, timing, and the available S-3 capacity.

At June 30, 2026, the company reported $26,186 of cash and a quarterly operating cash outflow of $6.03 million; the supplied comparison places that cash balance at 0.4 days of the last reported quarterly operating cash use.

Sources and calculations
  • Available liquidity against the last reported quarterly operating outflow, in days at that rate $26,186 / ($6,030,510 / 91) = 0.4 days
Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
ATM Aggregate Offering Capacity $30,000,000 Maximum aggregate offering price of common stock that may be sold under the ATM agreement
Sales Agent Commission Rate 2.0% of aggregate gross proceeds Commission payable to Aegis Capital on each sale of shares under the ATM
Reimbursable Counsel and Related Expenses Cap $37,500 Maximum aggregate documented fees and costs of Aegis Capital’s legal counsel reimbursable by the company on entry into the ATM
Shelf Registration File Number 333-297939 Form S-3 shelf registration statement used for the ATM program
Common Stock Par Value $0.01 per share Par value of VisionWave’s common stock eligible for sale under the ATM
Redeemable Warrant Exercise Price $11.50 per share Exercise price of each redeemable warrant for one share of common stock listed as VWAVW
At The Market Issuance Sales Agreement financial
"entered into an At The Market Issuance Sales Agreement (the “ATM Agreement”)"
shelf registration statement regulatory
"pursuant to a shelf registration statement on Form S-3 and the related prospectus"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
prospectus supplement regulatory
"and prospectus supplement related to the offering of Shares filed with the SEC"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
at the market offering financial
"deemed to be an “at the market offering” as defined in Rule 415"
An at-the-market offering is a way a company raises cash by selling newly issued shares directly into the open market at prevailing prices, rather than all at once in a single deal. Think of it like turning a faucet on to drip shares into trading at current prices when needed; it gives the company flexibility to raise funds over time but can dilute existing shareholders and potentially affect the stock price, which investors should monitor.
General Instruction I.B.6 regulatory
"including General Instruction I.B.6 thereof, if applicable"
indemnification and contribution regulatory
"agreed to provide the Agent with customary indemnification and contribution rights"
Offering Type ATM
Use of Proceeds Net proceeds from sales of shares, if any, are intended for general corporate and working capital purposes.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ATM equity program did VisionWave Holdings (VWAV) announce?

VisionWave entered into an At The Market Issuance Sales Agreement with Aegis Capital Corp., allowing the sale of its common stock from time to time with an aggregate offering price of up to $30,000,000 under its existing Form S-3 shelf registration.

How much stock can VisionWave (VWAV) sell under the new ATM agreement?

VisionWave may offer and sell shares of common stock with an aggregate offering price of up to $30,000,000, limited further by its then-current Form S-3 shelf registration capacity, including General Instruction I.B.6 if applicable.

What commission will Aegis Capital receive in the VisionWave (VWAV) ATM?

Aegis Capital, as sales agent, will receive a 2.0% commission on the aggregate gross proceeds from each sale of VisionWave’s common stock under the ATM agreement, plus specified reimbursable expenses up to $37,500 for its legal counsel and related due diligence fees.

How does VisionWave (VWAV) plan to use proceeds from the ATM sales?

VisionWave currently intends to use the net proceeds from any sale of shares under the ATM for general corporate and working capital purposes, while noting that actual amounts and timing of expenditures may vary and management retains broad discretion over allocation.

Where can VisionWave (VWAV) shares be sold under the ATM program?

Shares may be sold in at-the-market offerings on the Nasdaq Global Market, on any other existing trading market, directly to Aegis as principal in negotiated transactions, through a market maker, or by any other method permitted by law.

Is VisionWave (VWAV) required to sell shares under the ATM agreement?

No. VisionWave is not obligated to make any sales under the ATM agreement, and Aegis is not obligated to purchase shares as principal except as separately agreed. There is no assurance that any shares will be sold, or at what price or in what amounts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
false 0002038439 0002038439 2026-09-18 2026-09-18 0002038439 VWAV:CommonStockParValue0.01PerShareMember 2026-09-18 2026-09-18 0002038439 VWAV:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member 2026-09-18 2026-09-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 18, 2026

 

VisionWave Holdings, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-42741   99-5002777

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

 

300 Delaware Ave., Suite 210 #301

Wilmington, DE

  19801
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (302) 305-4790

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.01 per share   VWAV   The Nasdaq Stock Market LLC
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50   VWAVW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

On September 18, 2026, VisionWave Holdings, Inc. (the “Company”), entered into an At The Market Issuance Sales Agreement (the “ATM Agreement”) with Aegis Capital Corp., as agent (the “Agent”), pursuant to which the Company may offer and sell, from time to time through the Agent, shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), having an aggregate offering price of up to $30,000,000 (the “Shares”).

 

The offer and sale of the Shares will be made pursuant to a shelf registration statement on Form S-3 and the related prospectus (File No. 333-297939) (the “Registration Statement”) filed by the Company with the Securities and Exchange Commission (the “SEC”) on August 3, 2026, as amended and declared effective by the SEC on September 1, 2026, under the Securities Act of 1933, as amended (the “Securities Act”), and prospectus supplement related to the offering of Shares filed with the SEC on September 18, 2026..

 

Pursuant to the ATM Agreement, the Agent may sell the Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act, including sales made directly on the Nasdaq Global Market or on any other existing trading market or directly to Agent as principal in negotiated transactions for the Common Stock, to or through a market maker or any other method permitted by law. The Agent will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the Shares from time to time, based upon instructions from the Company, including any price or size limits or other customary parameters or conditions the Company may impose.

 

Under the terms of the ATM Agreement, in no event will the Company issue or sell through the Agent such number or dollar amount of shares of Common Stock that would exceed the lesser of (i) $30.0 million or (ii) the Company’s maximum offering amount permitted to be sold under its then current shelf registration statement capacity on Form S-3 (including General Instruction I.B.6 thereof, if applicable).

 

The Company is not obligated to make any sales of the Shares under the ATM Agreement, and the Agent is not obligated to purchase any Shares on a principal basis pursuant to the ATM Agreement, except as otherwise specifically agreed by the Agent and the Company in a separate agreement. No assurance can be given that the Company will sell any Shares under the ATM Agreement, or if such sales occur, no assurance can be given as to the price or number of Shares that will be sold, or the dates on which any such sales will take place. The offering pursuant to the ATM Agreement will terminate upon the earlier of (i) the issuance and sale of all shares of our common stock subject to the ATM Agreement, or (ii) the termination of the ATM Agreement as permitted therein.

 

The Company will pay the Agent a commission rate equal to 2.0% of the aggregate gross proceeds from each sale of Shares and has agreed to provide the Agent with customary indemnification and contribution rights. The Company will also reimburse the Agent for certain specified expenses in connection with entering into the ATM Agreement, including for the documented fees and costs of its legal counsel reasonably incurred in connection with entering into the transactions contemplated by the ATM Agreement in an amount not to exceed $37,500 in the aggregate, in addition to periodic due diligence fees, plus any incidental expense incurred by the Agent in connection therewith. The ATM Agreement contains customary representations and warranties and conditions to the sale of the Shares pursuant thereto.

 

We currently intend to use the net proceeds from the sale of Shares, if any, for general corporate and working capital purposes, however the amounts and timing of our actual expenditures may vary significantly depending on numerous factors, and as a result, our management will retain broad discretion over the allocation of the net proceeds from the sale of Shares.

 

 

 

The foregoing description of the ATM Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The opinion of Sheppard, Mullin, Richter & Hampton LLP, the Company’s counsel, regarding the validity of the Shares that will be issued pursuant to the ATM Agreement, is also filed herewith as Exhibit 5.1.

 

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Common Stock discussed herein, nor shall there be any offer, solicitation, or sale of common stock in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
5.1   Opinion of Sheppard, Mullin, Richter & Hampton LLP
10.1   At The Market Issuance Sales Agreement dated September 18, 2026 between VisionWave Holdings, Inc. and Aegis Capital Corp.
23.1   Consent of Sheppard, Mullin, Richter & Hampton LLP (included in Exhibit 5.1)
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  VISIONWAVE HOLDINGS INC.
     
Date: September 18, 2026 By: /s/ Douglas Davis 
  Name: Douglas Davis
  Title: Chief Executive Officer

 

 

 

Filing Exhibits & Attachments

6 documents

Keep reading